Celsion Corporation to Present at NobleConXV – Noble Capital Markets’ 15th Annual Investor Conference
24 janv. 2019 11h30 HE
|
Celsion CORP
LAWRENCEVILLE, N.J., Jan. 24, 2019 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that Jeffrey Church, Celsion’s Executive Vice...
Celsion Announces Publication of ThermoDox® Study Results in Radiology
17 janv. 2019 08h30 HE
|
Celsion CORP
Publication Highlights Phase I Data Supporting Safety and Feasibility of Treatment with ThermoDox® and Non-Invasive, Focused Ultrasound University of Oxford’s Findings Provide Additional...
Celsion Announces Presentation of GEN-1 Data at Upcoming ASCO-SITC Clinical Immuno-Oncology Symposium
15 janv. 2019 08h30 HE
|
Celsion CORP
Data to be Highlighted During Oral Session on March 2, 2019 LAWRENCEVILLE, N.J., Jan. 15, 2019 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today...
Data Monitoring Committee (DMC) Completes Planned Safety and Data Review of Celsion’s Phase III OPTIMA Study of ThermoDox® for Treatment of Primary Liver Cancer
18 déc. 2018 08h00 HE
|
Celsion CORP
Current Combined, Blinded Progression-Free Survival (PFS) Rate for Both Treatment Arms Reaches 21.2 Months Compared to 19.8 Months for the Intent-To-Treat (ITT) Population in the HEAT Study Post-Hoc...
Celsion Receives $11.1 Million Allocation Through the New Jersey Technology Business Tax Certificate Transfer (NOL) Program
03 déc. 2018 09h15 HE
|
Celsion CORP
Non-Dilutive Funding Strengthens Balance Sheet Proceeds Equate to More Than $0.55 Per Share LAWRENCEVILLE, N.J., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an...
Celsion Corporation Reports Third Quarter 2018 Financial Results and Provides Business Update
14 nov. 2018 16h30 HE
|
Celsion CORP
ThermoDox® Phase III OPTIMA Study Fully Enrolled in August; First Pre-Planned Efficacy Analysis Expected in Mid-2019 GEN-1 Phase I/II OVATION 2 Study Enrolling Patients; First Look at...
Celsion Corporation to Hold Third Quarter 2018 Financial Results Conference Call on Thursday, November 15, 2018
08 nov. 2018 09h15 HE
|
Celsion CORP
LAWRENCEVILLE, N.J, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss financial results for the quarter...
Celsion Announces Progression-Free Survival Data From GEN-1 Phase I Immuno-Oncology Study of Patients with Stage III/IV Ovarian Cancer
24 oct. 2018 09h25 HE
|
Celsion CORP
Single Arm Study Demonstrated a Median Progression-Free Survival (PFS) of 24.3 Months for Patients Treated per Protocol; Patients in the Intent-to-Treat Population had a Median PFS of 17.1 months...
Celsion Announces Publication Highlighting the Potential of Celsion's Gene-Mediated Immunotherapy to Improve Administration of IL-12 and Progression-Free Survival in Ovarian Cancer Patients
22 oct. 2018 09h20 HE
|
Celsion CORP
Analysis in peer-reviewed journal, Future Oncology, outlines the ability of GEN-1, a non-viral nanoparticle delivery system, to support persistent local production of IL-12 LAWRENCEVILLE, N.J,...
Celsion Corporation Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
03 oct. 2018 17h15 HE
|
Celsion CORP
LAWRENCEVILLE, N.J., Oct. 03, 2018 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that on September 28, 2018, the Compensation...